ISCO International Stem Cell CORP
Pharmaceutical Preparations · OTC · SEC CIK 1355790 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.4%
TTM net income YoY-141.5%
TTM EPS YoY-75.0%
Revenue 3-yr CAGR5.7%
Net income 3-yr CAGR—
Margins
Gross margin55.0%
Operating margin-4.7%
Net margin-6.1%
FCF margin3.5%
EBITDA margin-2.9%
Returns
ROE—
ROA-11.0%
ROIC (approx.)—
Asset turnover1.79x
Leverage & solvency
Liabilities / assets98.6%
Debt / equity—
Current ratio0.79x
Interest coverage-3.15x
Cash quality & payout
Operating cash flow / net income-0.63x
Accruals ratio-17.9%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.67M | $2.31M | $2.15M | $2.37M | $2.45M | $2.13M | $2.45M | $2.18M |
| Cost of revenue | $1.22M | $954,000 | $1.07M | $1.05M | $927,000 | $992,000 | $990,000 | $974,000 |
| Gross profit | $1.46M | $1.36M | $1.09M | $1.32M | $1.52M | $1.14M | $1.46M | $1.21M |
| R&D expense | $155,000 | $156,000 | $177,000 | $158,000 | $162,000 | $187,000 | $210,000 | $187,000 |
| SG&A expense | $1.06M | $1.12M | $946,000 | $789,000 | $905,000 | $892,000 | $907,000 | $816,000 |
| Operating income | -$35,000 | -$190,000 | -$313,000 | $94,000 | $167,000 | -$215,000 | $51,000 | -$90,000 |
| Interest expense | $34,000 | $35,000 | $35,000 | $37,000 | $38,000 | $41,000 | $39,000 | $35,000 |
| Net income | -$71,000 | -$220,000 | -$348,000 | $57,000 | $129,000 | -$256,000 | $11,000 | -$125,000 |
| EBITDA | -$7,000 | -$156,000 | -$259,000 | $150,000 | $221,000 | -$160,000 | $105,000 | -$37,000 |
| EPS (basic) | -0.01 | -0.03 | — | 0.00 | 0.01 | -0.03 | — | -0.02 |
| EPS (diluted) | -0.01 | -0.03 | — | 0.00 | 0.01 | -0.03 | — | -0.02 |
| Weighted avg. shares (diluted) | 8.00M | 8.00M | — | 8.17M | 8.00M | 8.00M | — | 8.00M |
| Balance sheet | ||||||||
| Cash & equivalents | $1.09M | $933,000 | $993,000 | $966,000 | $920,000 | $1.45M | $1.23M | $1.31M |
| Receivables | $959,000 | $791,000 | $723,000 | $1.01M | $1.10M | $851,000 | $1.06M | $680,000 |
| Inventory | $1.69M | $1.77M | $1.51M | $1.59M | $1.55M | $1.26M | $1.15M | $1.38M |
| Current assets | $3.92M | $3.81M | $3.41M | $3.73M | $3.84M | $3.84M | $3.56M | $3.49M |
| PP&E, net | $159,000 | $169,000 | $160,000 | $192,000 | $225,000 | $227,000 | $257,000 | $290,000 |
| Intangibles | $515,000 | $633,000 | $644,000 | $661,000 | $681,000 | $701,000 | $721,000 | $739,000 |
| Total assets | $5.06M | $5.13M | $4.82M | $5.28M | $5.55M | $5.62M | $5.17M | $5.18M |
| Current liabilities | $4.98M | $5.05M | $4.58M | $4.66M | $4.94M | $5.11M | $4.69M | $4.72M |
| Total liabilities | $4.98M | $5.05M | $4.58M | $4.76M | $5.14M | $5.41M | $4.80M | $4.92M |
| Shareholders' equity | -$4.23M | -$4.22M | -$4.06M | -$3.78M | -$3.90M | -$4.09M | -$3.93M | -$4.04M |
| Shares outstanding | 8.00M | 8.00M | 8.00M | 8.00M | 8.00M | 8.00M | 8.00M | 8.00M |
| Cash flow statement | ||||||||
| Operating cash flow | $167,000 | $121,000 | $32,000 | $49,000 | -$300,000 | $227,000 | -$74,000 | $257,000 |
| Capital expenditure | $7,000 | $23,000 | $3,000 | $3,000 | $32,000 | $5,000 | $1,000 | $37,000 |
| Free cash flow | $160,000 | $98,000 | $29,000 | $46,000 | -$332,000 | $222,000 | -$75,000 | $220,000 |
| Investing cash flow | -$11,000 | -$31,000 | -$5,000 | -$3,000 | -$32,000 | -$5,000 | -$3,000 | -$40,000 |
| Financing cash flow | $0 | -$150,000 | $0 | $0 | — | — | $0 | — |
| Depreciation & amortization | $28,000 | $34,000 | $54,000 | $56,000 | $54,000 | $55,000 | $54,000 | $53,000 |
| Stock-based compensation | $59,000 | $64,000 | $64,000 | $63,000 | $61,000 | $100,000 | $100,000 | $100,000 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.